Dr Pardee Discusses a Phase I Study of CPI613 in Advanced Hematologic Malignancies

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=eIbi7hfoms8

Timothy S. Pardee, MD, Assistant Professor, Hematology Oncology, Wake Forest University Baptist Medical Center, describes a phase I study of the first-in-class pyruvate dehydrogenase complex inhibitor CPI-613 in patients with advanced hematologic malignancies. • More on hematology: http://www.onclive.com/specialty/hema...

#############################

New on site